Close

Bionomics commences BNC10 manufacturing activities

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fluid Path Integrity: Ensuring Purity in Biomanufacturing

In the high-stakes arena of biomanufacturing, where tiny contaminants...

GMP Fluid Handling: Regulatory Compliance Explained

Fluid Handling in GMP Manufacturing: The Essence of Regulatory...

Single-Use Technologies in Biopharma Transform Manufacturing

The biopharmaceutical sector is being revolutionized by the demand...

Advances in Aseptic fluid transfer solutions

Sterility and Cross-Contamination: The Cornerstones of Modern Biopharma Manufacturing Biopharmaceutical...

Australia-based international biotechnology company Bionomics has commenced manufacturing activities for anti-cancer stem cell candidate BNC10.

Lonza will manufacture BNC101 at Slough facility in the UK. Bionomics CEO and managing director Dr Deborah Rathjen said, “The start of manufacturing activities for BNC101 signals a significant step towards clinical trials. We anticipate that Bionomics will commence clinical trials of BNC101 in 2014.”

Various preclinical studies revealed that BNC101 is functional active against high value cancer stem cell receptor LGR5.

Animal studies involving primary colorectal cancer patient samples with multiple underlying gene mutations revealed that BNC101 reduces cancer stem cell frequency and prevents tumor re-growth.

 

Latest stories